Answers are grounded in this paper and cite their sources.
Metastatic melanoma has a poor prognosis due to resistance to multiple chemotherapy regimens. The mainstay of treatment remains dacarbazine, with cisplatin being a commonly used alternative. Melanoma displays marked resistance to the DNA-damaging effects of these drugs. Intrinsic and acquired resistance involves multiple cellular pathways of damage recognition, repair and apoptosis. Increased understanding of these pathways is identifying novel targets that it is hoped will make inroads into the treatment of this lethal disease.
No takes yet. Share an insight, caveat, or question.
Bradbury et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: